Gelonghui, March 18 | Yahong Pharmaceutical (688176.SH) announced that recently, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. product APL1702 for treating high-grade cervical squamous intraepithelial lesion (HSIL) prospective, randomized, double-blind, placebo-controlled international multi-center phase III clinical trial results were selected for the 2024 European Genital Infection and Oncology Research Organization Conference (EUROGIN) and 2024 American Gynecological Oncology The Society's Annual Meeting (SGO) also published the study's core data on efficacy and safety in the form of oral reports at the conference. APL-1702 is a photodynamic therapy product integrating medicine and equipment. As a topical non-surgical treatment, it is used to treat HSIL.

This study is a prospective, randomized, double-blind, placebo-controlled international multicenter phase III clinical trial to evaluate the efficacy and safety of APL-1702 on high-grade cervical squamous intraepithelial lesion (HSIL). Academician Lang Jinghe from Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences was the main researcher. 402 eligible patients from China, Germany, the Netherlands and other countries were randomized and enrolled in this study. The completed statistical analysis results showed that the study had reached the main efficacy end point and was safe.